Download this complimentary Expert Insights eBook today — featuring an exclusive interview with Prof. Kyoji Tsuchikama
Tumor heterogeneity limits ADC efficacy. Multi-step manufacturing slows development. This eBook brings together AI-guided payload design, a two-hour one-pot synthesis method, and advanced LC-MS characterization — three innovations reshaping how ADCs move from bench to clinic.
Inside this eBook:
- AI-guided payload design for enhanced bystander killing in heterogeneous tumors
- One-pot ADC synthesis from unpurified antibodies — days reduced to ~2 hours
- 26 conjugation sites mapped with <3 ppm mass accuracy via LC/Q-TOF
- Expert interview: Prof. Kyoji Tsuchikama on dual-drug platforms and AI in ADC design
Click “LOOK INSIDE” to download the PDF now.
More Information
ADCs combine the targeting precision of monoclonal antibodies with potent cytotoxic payloads, delivering chemotherapy directly to tumor cells. With over 15 FDA-approved ADCs and hundreds in clinical development, the field is advancing rapidly — yet two bottlenecks persist: heterogeneous antigen expression that lets resistant cells survive, and costly multi-step manufacturing. This collection presents research tackling both challenges head-on, from computational payload optimization and streamlined synthesis to rigorous site-specific analytical characterization. An in-depth interview with Prof. Tsuchikama adds perspective on where the field is heading next.
Brought to you by
Sponsored by
